A controversial diabetes drug has shown “really hopeful” signs of “potentially reducing cancer” in some unpublished studies, a physician has claimed.
Dr Tyna Moore, a naturopathic and chiropractic physician and expert in holistic regenerative medicine, discussed the potential benefits of Ozempic with Steven Bartlett during an episode of The Diary of a CEO podcast this week.
She said some people have been criticising Ozempic as “evil”, but it has “mind-blowing” health benefits, causing “really profound changes” in people and potentially targeting cancers that patients “don’t come back from readily”.
Dr Moore later said: “There are other data sets coming out that haven’t been published yet are showing really good, really hopeful and positive impacts on potentially reducing cancer risk.
“And they’re correlative, not causative, so we can’t put our finger on it and say these reduce cancer, but they looked at a, you know, over a million people that were type 2 diabetics that were on semaglutide.”
Dr Moore continued: “And they found a significant reduction in different types of cancer that are obesity related in comparison to the folks who were not taking GLP-1s.
“And those were the cancers you don’t want – the ovarian, the pancreatic, the colon, the types of cancers that are, you know, you don’t come back from readily, and so that’s very exciting.”
Ozempic is one of several brand names for semaglutide, the active ingredient in injections used to treat diabetes; some patients have also lost weight when using the drug, but it isn’t licensed for this purpose in the UK.
However, Wegovy, another semaglutide medication, is licensed and approved by the National Institute for Health and Care Excellence (NICE) for the management of obesity, according to NHS Kent and Medway.
Ozempic has made waves among celebrities, with Rebel Wilson and Sharon Osbourne reportedly taking it for weight loss purposes, and the UK has seen a surge in demand for the drug.
Earlier this year, pharmacies reported rises of more than 400 percent in demand for consultations from those wanting to access the drugs.
The explosion in demand was thought to be triggered by research showing that overweight patients with heart disease who took semaglutide for at least three years slashed their risk of heart attack, stroke, or cardiac death by a fifth.
Controversy surrounds Ozempic, however, mostly over a reported side effect whereby patients suffer from nausea when thinking about food, as well as potential links to pancreatitis, gallstones and a possible risk of thyroid cancer, Sky News reported in 2022.
But Dr Moore claimed that many people were being “overdosed for weight-loss” and suggested that the drug could have benefits for a range of serious health conditions.
She said: “What I was finding in the literature was not at all adding up to what I was hearing, and then there were all of these other benefits that were just mind-blowing.”
Dr Moore continued: “You know, benefits on healing and reversing type 1 diabetes, healing and reversing neurocognitive conditions like Parkinson’s and Alzheimer’s, efficacy with alcohol cessation.
“People who were you know, alcohol abuse syndrome, using it for that. People who also had this type of HLA-B27; it’s a genetic propensity towards these, spondyloarthritises like psoriatic arthritis, rheumatoid arthritis, those kinds of things.
“Having, showing efficacy for that, and as I started speaking out about it, I was getting messages back from people, telling me their stories, hundred and hundreds of people telling me their stories.”